- Metabolite
- HMDB0015595 (Nilotinib)
- Term
- Nilotinib Inhibition of BCR-ABL
- Definition
- the cause of cml pathophysiology is the bcr-abl fusion protein - the result of a genetic abnormality known as the philadelphia chromosome in which abelson murine leukemia viral oncogene homolog 1 (abl1) translocates within the breakpoint cluster region (bcr) gene on chromosome 22. bcr-abl is a cytoplasm-targeted constitutively active tyrosine kinase that activates several oncogenic pathways which promote increased cell proliferation and survival including the mapk/erk pathway, the jak-stat pathway, and the pi3k/akt pathway.
- Parent Term
- Biochemical pathway
- Parent Definition
- A linked series of chemical reactions that occur in a defined order within or between organism cells, and lead to a known function or end product.
- Other Metabolites Mapped to 'Nilotinib Inhibition of BCR-ABL'
HMDB0015595 (Nilotinib) References